文献速递冠心病

高危NSTEMI患者造影时机与结局:TAO试验分析

Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban).
PubMed 文献 · Circulation · 2017-09-11

基于TAO试验的事后分析,纳入GRACE评分>140的NSTEMI患者4071例,按入院至冠脉造影时间分为<12小时、12-24小时和≥24小时三组。以≥24小时为参照,<12小时造影与180天全因死亡和心肌梗死复合终点风险降低相关(OR 0.71,95%CI 0.55-0.91),而12-24小时造影无显著关联,出血并发症无差异。

要点

  • GRACE评分>140的NSTEMI患者,入院12小时内造影与180天缺血结局风险降低相关。
  • 12-24小时造影相比≥24小时未显著降低主要缺血终点风险。
  • 不同造影时机组间出血并发症无差异。

核心结论

  • 高危NSTEMI患者入院12小时内行冠脉造影与180天缺血结局风险降低相关。

研究设计与样本

  • TAO试验的事后分析,纳入GRACE评分>140且计划72小时内行冠脉造影的NSTEMI患者,共4071例接受造影。

主要发现

  • 造影时间<12小时组1648例(40.5%),12-24小时组1420例(34.9%),≥24小时组1003例(24.6%)。
  • 以≥24小时为参照,12-24小时造影与180天主要缺血终点无显著关联(OR 0.96,95%CI 0.75-1.23)。
  • <12小时造影与180天死亡和心肌梗死风险降低相关(OR 0.71,95%CI 0.55-0.91)。
  • 与12-24小时造影相比,<12小时造影与死亡和心肌梗死风险降低相关(OR 0.76,95%CI 0.61-0.94;P=0.01)。
  • 不同造影时机组间出血并发症无差异。

关键数值与推荐

  • 主要缺血终点为随机化后180天内全因死亡和心肌梗死的复合终点。

临床怎么用

  • 对于GRACE评分>140的高危NSTEMI患者,可考虑在入院12小时内行冠脉造影以降低缺血事件风险。

局限性

  • 本研究为TAO试验的事后分析,非随机比较造影时机,可能存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with non-ST-segment-elevation myocardial infarction (NSTEMI) and GRACE (Global Registry of Acute Coronary Events) score >140, coronary angiography (CAG) is recommended by European and American guidelines within 24 hours. We sought to study the association of very early (ie, ≤12 hours), early (12-24 hours), and delayed (>24 hours) CAG in patients with NSTEMI with GRACE score >140 with ischemic outcomes. METHODS: The TAO trial (Treatment of Acute Coronary Syndrome With Otamixaban) randomized patients with NSTEMI and CAG scheduled within 72 hours to heparin plus eptifibatide versus otamixaban. In this post hoc analysis, patients with a GRACE score >140 were categorized into 3 groups according to timing of CAG from admission (<12, ≥12-<24, and ≥24 hours). The primary ischemic outcome was the composite of all-cause death and myocardial infarction within 180 days of randomization. RESULTS: CAG was performed in 4071 patients (<12 hours, n=1648 [40.5%]; 12-24 hours, n=1420 [34.9%]; ≥24 hours, n=1003 [24.6%]). With CAG ≥24 hours as a reference, CAG from 12 to 24 hours was not associated with a lower risk of primary ischemic outcome at 180 days (odds ratio, 0.96; 95% confidence interval, 0.75-1.23), whereas CAG <12 hours was associated with a lower risk of death and myocardial infarction (odds ratio, 0.71; 95% confidence interval, 0.55-0.91). Performing CAG <12 hours was also associated with a lower risk of death and myocardial infarction (odds ratio, 0.76; 95% confidence interval, 0.61-0.94; P=0.01) compared with CAG performed at 12 to 24 hours. No difference was observed in bleeding complications. CONCLUSIONS: In patients with high-risk NSTEMI, undergoing CAG within the initial 12 hours after admission (as opposed to later, either 12-24 or ≥24 hours) was associated with lower risk of ischemic outcomes at 180 days.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Deharo P, Ducrocq G, Bode C, et al. Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation. 2017. PMID: 28893843. doi:10.1161/CIRCULATIONAHA.117.029779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。